After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Arbutus Biopharma Corp is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Arbutus Biopharma Corp is $538.47M. A total of 8.08 million shares were traded on the day, compared to an average of 1.13M shares.
In the most recent transaction, McElhaugh Michael J. sold 10,164 shares of ABUS for 2.31 per share on Feb 02 ’24. After the transaction, the Interim President & CEO now owns 1,504,793 company shares. In a previous transaction on Feb 02 ’24, Sofia Michael J. sold 9,982 shares at 2.31 per share. ABUS shares that Chief Scientific Officer owns now total 1,485,121.
Among the insiders who sold shares, HASTINGS DAVID C disposed of 9,593 shares on Feb 02 ’24 at a per-share price of $2.31. This resulted in the Chief Financial Officer holding 181,907 shares of ABUS after the transaction. In another insider transaction, Sims Karen sold 4,358 shares at $2.31 per share on Feb 02 ’24. Company shares held by the Chief Medical Officer now total 125,542.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ABUS has a high of $3.25 and a low of $1.69.
As of this writing, ABUS has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.12 in the last quarter, which was -9.10% lower than expectations of -$0.11.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.
